We have located links that may give you full text access.
T-lymphocyte-derived enkephalins reduce T h 1/T h 17 colitis and associated pain in mice.
Journal of Gastroenterology 2018 Februrary
BACKGROUND: Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal Th 1/Th 17-associated inflammation, enkephalins released by colitogenic CD4+ T lymphocytes relieve inflammation-induced visceral pain. The present study aims to investigate whether mucosal T-cell-derived enkephalins also exhibit a potent anti-inflammatory activity as described for exogenous opioid drugs in Th 1/Th 17-associated colitis.
METHODS: The anti-inflammatory effects of endogenous opioids were investigated in both Th 1/Th 17-associated (transfer of CD4+ CD45RBhigh T lymphocytes) and Th 2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4+ CD45RBhigh T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred.
RESULTS: Peripheral opioid receptor blockade increases the severity of Th 1/Th 17-induced colitis and attenuates Th 2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a Th 2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4+ CD45RBhigh T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury.
CONCLUSIONS: Endogenous opioids, including T-cell-derived enkephalins, promote a Th 2-type immune response, which, depending on the context, may either attenuate (Th 1/Th 17-associated) or aggravate (Th 2-associated) intestinal inflammation.
METHODS: The anti-inflammatory effects of endogenous opioids were investigated in both Th 1/Th 17-associated (transfer of CD4+ CD45RBhigh T lymphocytes) and Th 2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4+ CD45RBhigh T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred.
RESULTS: Peripheral opioid receptor blockade increases the severity of Th 1/Th 17-induced colitis and attenuates Th 2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a Th 2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4+ CD45RBhigh T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury.
CONCLUSIONS: Endogenous opioids, including T-cell-derived enkephalins, promote a Th 2-type immune response, which, depending on the context, may either attenuate (Th 1/Th 17-associated) or aggravate (Th 2-associated) intestinal inflammation.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app